E*Trade shows it's trading. .0182. 8,379 shares traded.

Thanks for keeping us up to date on this stock. I am hoping for the best and think that we will be rewarded soon.


Warren

Why are we down a buck today? I see no news good or bad.

It does not appear on the Halt list.

http://www.nasdaqtrader.com/trader.aspx?id=TradeHalts

"Who would invest $70K in a dumpster fire?"

So maybe I should keep my GTC order to sell a bunch active?

"We got played by a miserable lying sack of dogsh!t"

POST OF THE YEAR . . .

I don't think Brilacidin was given out that early was it???

Can you tell us which Regional Bio Lab run by the US Government?

I see many and would like to know which one is the one.

Thanks

Google is your best friend:

Why the $GME MOASS (Mother of All Short Squeezes)

And a MOASS is . . .

Saw this on my AOL this morning on their Welcome Screen:
why do I feel so left out???

Study confirms GSK-Vir antibody drug reduces hospitalization,
death in COVID-19 patients
Reuters
June 21, 2021, 9:34 AM
(Reuters) - GlaxoSmithKline Plc and Vir Biotechnology said on Monday final results from a late-stage study of their monoclonal antibody confirmed it significantly reduced hospitalization and death among high-risk COVID-19 patients when given early in the disease.

The treatment, sotrovimab, received an emergency use authorization from the U.S. Food and Drug Administration in May, while the European Union's drug regulator has also backed it.

The drugmakers also said on Monday the U.S. National Institutes of Health (NIH) has recommended sotrovimab to treat high-risk, non-hospitalized patients with mild-to-moderate COVID-19.

The treatment appeared to "retain activity" against current variants of concern and interest, the agency said in its updated guidelines.

In a study of 1,057 patients, sotrovimab resulted in a 79% reduction in risk of hospitalization for more than 24 hours or death due to any cause, the companies said on Monday.

Sotrovimab belongs to a class of drugs called monoclonal antibodies that mimic the natural antibodies the body generates to fight off infection.

Similar therapies developed by rivals Regeneron and Eli Lilly have been approved by U.S. regulators for treating non-hospitalized COVID-19 patients.

GSK said it was now testing sotrovimab as an intramuscular shot, which is more convenient than by intravenous drip, the current mode of administration.

Vir's shares rose about 2% in premarket trading, while GSK's stock was flat.

(Reporting by Vishwadha Chander in Bengaluru; Additional reporting by Ludwig Burger in Frankfurt; Editing by Sriraj Kalluvila)

Thanks for posting the list.

Thanks Dane. . .

I thought that I read somewhere, Google perhaps, that trials were going on right now and would be finished in June of this year, but this latest PR states that they only have 50% filled for the trials.

Could someone straighten me out on this point please?

And, can they do the clinical trial with only 50% fulfillment, which could mean they are in progress now?

Thanks much

POST OF THE MONTH (SO FAR)

I'm seeing some big bid sizes coming thru, like in the 400,000 area, as ask sizes are like 5,000.

Don't see any news as yet.

Definitely Post of the Month

I hope this doesn't turn into another IMDS. Anyone here involved in this one?

God Bless Alan.

I think some of you could have bought out the company when it was down to a nickel. lol

"Will illegal aliens be able to get Brilacidin funded on the taxpayers dime?"

Only if they are "residents" of California.

Takeover Question:

IF Brilacidin is such a great drug (and we hope that it is), why haven't any of the bigger drug companies tried to get control of the company?

How is Pfizer and BioNTech receive FastTrack before IPIX has, when it must be well known that IPIX has such a promising product to combat this virus?

Politics or what???

There must be a rumor circulating around because of the large volumn of 3.069 mil shares traded at this time. 12:12.

Just my opinion but . . .

Thanks for the very interesting information Farrell90.

Going to be a very interesting week ahead.

Speaking of a quick runup in this stock, the pros always said to sell half and let the rest run.

Do many of you still hold this to be true?

It would, of course, depend on what type of good news they at first come out with, whether we should sell part or all of it.

Just wondering what you all would say to this strategy.

Yes, now I see 6 shares but no price showing, just a bid of 4.10 and ask of 6.84 and the high and low of .053

E-Trade doesn't show a change on my portfolio yet.

I started buying this back in 2011, and more later on. Would love to see it jump over some hoops. lol

Any members who bought this as Antigenics years ago?
The reason I ask is I did but broker refuses to upgrade it to AGEN.
Any info you could supply would help me straighten it out.

lol

got a little volume here.

No movement, no news. yet.

Thanks for keeping us posted.

And what is the QB category on the OTC?

Yes, we all know that.

I was asking why the Bid Size is 151 mil and the Ask Size is only 4 mil.
Seems that someone knows something we don't.

I don't feel there will be any movement in this stock until they start the procedure for an American FDA approval as they did in the old days.

And we all know what happened after that.

Just my opinion tho . . .

I don't understand why this stock is not moving up because the Bid Size is 151 mil and the Ask Size is only 4 mil and there hasn't been any news out for quite a few months.

Ready to give up on it.

I can recall that back in those days, 2014, the Grables were running the company, her and her daughter, whose name escapes me.

it sure would be nice

I sure hope you're right George.

Yes, she is going that route now. quite a difference in the price.

thanks

Thanks for the responses. She is calling dermotologist to see about an inexpensive substitute.

Maybe I should call Leo. . . lol